Immunological aspects of hematopoietic stem cell transplantation for hematologic malignancies and some immunological peculiarities of cancer radioimmunotherapy
https://doi.org/10.17650/1726-9784-2023-22-2-10-19
Abstract
This literature review provides basic information about the role of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes, acute myeloid leukemia, acute lymphoblastic leukemia. The recommendations for the use of stem cell transplantation are indicated. Conditioning regimens (myeloablative, non-myeloablative, reduced intensity), their advantages and disadvantages are considered. The issues of prevention and treatment of graft-versus-host disease, including graft preparation (T-cell depletion), extracorporeal photopheresis and mechanisms of graft-versus-tumor (-leukemia) reaction are highlighted. The historical milestones of theimmunotherapy development, the creation of therapeutic monoclonal antibodies, the development of targeted therapy, for example, conjugates of monoclonal antibodies with cytostatic drugs and radionuclides (targeted radionuclide therapy) are reported. Information about radioimmunotherapy as a method used for treatment of solid tumors and non-Hodgkin’s lymphoma, and information on the use of mesenchymal stem cells for the treatment and prevention of the graft-versus-host reaction are presented.
About the Authors
A. D. Shirin
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Anton Dmitrievich Shirin
24 Kashirskoe Shosse, Moscow 115522
O. Yu. Baranova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
V. V. Reshetnikova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
References
1. Valiev T.T., Shervashidze M.A., Osipova I.V. et al. Protocol ALLIC BFM 2002: outcomes of pediatric acute lymphoblastic leukemia treatment under multi-center clinical trial. Klinicheskaya onkogematologiya = Clinical Oncohematology 2022;15(2):119–29. (In Russ.). DOI: 10.21320/2500-2139-2022-15-2-119-129
2. Snowden J.A., Sánchez-Ortega I., Corbacioglu S. et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022;57(8):1217–39. DOI: 10.1038/s41409-022-01691-w
3. de Witte T., Oosterveld M., Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev 2007;21(1):49–59. DOI: 10.1016/j.blre.2006.03.002
4. Doubek M., Folber F., Koristek Z. et al. Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion. Ann Hematol 2009;88(9):881–7. DOI: 10.1007/s00277-009-0700-3
5. Liu X., Wu M., Peng Y. et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2014;23(9):1087–98. DOI: 10.3727/096368912X661319
6. EBMT annual report 2020. The EBMT Registry 2020. Available at: https://www.ebmt.org/annual-report-2020/ebmt-registry-2020
7. Shimomura Y., Hara M., Konuma T. et al. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplant 2021;56(10):2510–17. DOI: 10.1038/s41409-021-01324-8
8. Truong T.H., Jinca C., Mann G. et al. Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy. Front Pediatr 2021;9:782785. DOI: 10.3389/fped.2021.782785
9. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
10. Suciu S., Mandelli F., de Witte T. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102(4):1232–40. DOI: 10.1182/blood-2002-12-3714
11. Röllig C., Bornhäuser M., Thiede C. et al. Long-term prognosis of acute myeloid leukemia according to the new genetic riskclassification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011;29(20):2758–65. DOI: 10.1200/JCO.2010.32.8500
12. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
13. NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. Version 1.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
14. Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Onkogematologiya = Oncohematology 2020;15(3):12–26. (In Russ.). DOI: 10.17650/1818-8346-2020-15-2-19-28
15. Juric M.K., Ghimire S., Ogonek J. et al. Milestones of hematopoietic stem cell transplantation – from first human studies to current developments. Front Immunol 2016;7:470. DOI: 10.3389/fimmu.2016.00470
16. Melkova K.N., Petrova G.D., Gorbunova N.V. et al. Classification of conditioning regimens for bone marrow transplantation: historical background and current perspectives. Klinicheskaya onkogematologiya = Clinical Oncohematology 2017;10(4):494–500. (In Russ.). DOI: 10.21320/2500-2139-2017-10-4-494-500
17. Larson S., Carrasquillo J., Cheung N.K., Press O.W. Radioimmunotherapy of human tumours. Nat Rev Cancer 2015;15(6):347–60. DOI: 10.1038/nrc3925
18. Bertagnolli M.M. Radioimmunotherapy for colorectal cancer. Clin Cancer Res 2005;11(13):4637–8. DOI: 10.1158/1078-0432.ccr-05-0485
19. Cheung M.C., Haynes A.E., Stevens A. et al. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymph 2006;47(6):967–7. DOI: 10.1080/10428190600572582
20. Davies A.J., Rohatiner A.Z.S., Howell S. et al. Tositumomab and iodine I131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2004;22(8):1469–79. DOI: 10.1200/JCO.2004.06.055
21. Kwekkeboom D.J., de Herder W.W., Krenning E.P. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):173–85. DOI: 10.1016/j.ecl.2010.12.003
22. Schulz J., Rohracker M., Stiebler M. et al. Proof of therapeutic efficacy of a 177Lu-labeled neurotensin receptor 1 antagonist in a colon carcinoma xenograft model. J Nucl Med 2017;58(6):936–41. DOI: 10.2967/jnumed.116.185140
23. Baum R.P., Singh A., Schuchardt C. et al. 177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med 2018;59(5):809–14. DOI: 10.2967/jnumed.117.193847
24. Ghimire S., Weber D., Mavin E. et al. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol 2017;8:79. DOI: 10.3389/fimmu.2017.00079
25. Aliev T.Z., Machneva E.B., Sidorova N.V. et al. Skin damage after the hematopoietic stem cell transplantation. Literature review. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2020; 19(2):184–92. (In Russ.). DOI: 10.24287/1726-1708-2020-19-2-184-192
26. “Graft versus host” reaction. (In Russ.). Available at: https://medobr.com/news/reaktsiya-transplantat-protiv-khozyaina/.
27. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 2004; 10(1):1–7. DOI: 10.1097/00130404-200401000-00001
28. Choi E.S., Im H.J., Kim H. et al. Depletion of αβ+ T cells for a haploidentical hematopoietic stem cell transplantation in children. J Clin Apher 2018;33(4):521–8. DOI: 10.1002/jca.21634
29. Muffly L.S., Chin M., Kwon H.-S. et al. Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with nonmyeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation. J Clin Oncol. 2021;39(15_suppl):7035. DOI: 10.1200/jco.2021.39.15_suppl.7035
30. Schmaltz C. Graft versus leukemia and graft versus tumor activity. In: Encyclopedia of Cancer. Ed. by J.R. Bertino. 2nd edn. San Diego, Elsevier, 2002. P. 325–338. DOI: 10.1016/B0-12-227555-1/00094-0
31. Barnes D.W., Corp M.J., Loutit J.F., Neal F.E. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956;2(4993):626–7. DOI: 10.1136/bmj.2.4993.626
32. Mathé G., Amiel J.L., Schwarzenberg L. et al. Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemic effects. Blood 1965;25(2):179–96. DOI: 10.1182/blood.v25.2.179.179
33. Dickinson A.M., Norden J., Li S. et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol 2017;8:496. DOI: 10.3389/fimmu.2017.00496
34. Minculescu L., Sengeløv H. The role of gamma delta T cells in haematopoietic stem cell transplantation. Scand J Immunol 2015;81(6):459–68. DOI: 10.1111/sji.12289
35. Slesarchuk O.A., Babenko E.V., Semenova E.V. et al. Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation. Terapevticheskiy arkhiv = Therapeutic Archive 2013;85(7):26–33. (In Russ.).
36. Vose B.M., Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer 1979;24(5):579–85. DOI: 10.1002/ijc.2910240510
37. Guz I.V., Trachtman P.E. Extracorporeal photopheresis in the treatment of graft-versus-host disease. Onkogematologiya = Oncohematology 2016;11(1):47–51. (In Russ). DOI: 10.17650/1818-8346-2016-11-1-47-51
38. Bruserud Ø., Tvedt T.H.A., Paulsen P.Q. et al. Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. Cancer Immunol Immunother 2014;63(8):757–77. DOI: 10.1007/s00262-014-1578-z
39. Kiselevskiy M., Vlasenko R., Reshetnikova V. et al. Potential use of mesenchymal multipotent cells for hemopoietic stem cell transplantation: pro and contra. J Pediatr Hematol Oncol 2021;43(3):90–4. DOI: 10.1097/MPH.0000000000002065
40. Kiselevsky M.V., Vlasenko R.Ya., Stepanyan N.G. et al. Mesenchymal bone marrow stem cell secretion: is it immunosuppressive or pro-inflammatory? Kletochniye tekhnologii v biologii i medicine = Cell Technologies in Biology and Medicine 2021;3:171–5. (In Russ.). DOI: 10.47056/1814-3490-2021-3-171-175
Review
For citations:
Shirin A.D., Baranova O.Yu., Reshetnikova V.V. Immunological aspects of hematopoietic stem cell transplantation for hematologic malignancies and some immunological peculiarities of cancer radioimmunotherapy. Russian Journal of Biotherapy. 2023;22(2):10-19. (In Russ.) https://doi.org/10.17650/1726-9784-2023-22-2-10-19
Views:
308
Email this article 
